Search Result

Results for "

tight junction

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Gap Junction Protein (2) ACSL Family (1) Amino acid Transporter (1) Amylases (2) Amyloid-β (1) Anaplastic lymphoma kinase (ALK) (1) Antibiotic (2) Apoptosis (3) Bacterial (4) Biochemical Assay Reagents (1) Claudin (3) Drug Derivative (1) Endogenous Metabolite (5) FAAH (1) Ferroptosis (1) Fluorescent Dye (1) Galectin (1) Glucocorticoid Receptor (2) Glutathione Peroxidase (1) Glycosidase (2) HCV (2) Interleukin Related (3) METTL3 (1) nAChR (1) NADH Dehydrogenase (1) Natriuretic Peptide Receptor (NPR) (1) NF-κB (7) NOD-like Receptor (NLR) (2) P-glycoprotein (2) p38 MAPK (1) Potassium Channel (1) Reference Standards (8) SOD (1) TNF Receptor (2) Transthyretin (TTR) (1) Tyrosinase (1) α-synuclein (1)
By Research Areas:	Cancer (6) Cardiovascular Disease (2) Infection (4) Inflammation/Immunology (18) Metabolic Disease (15) Neurological Disease (8)
Oligonucleotides:	Pegylated Lipids (1) Polymers (1)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Antibodies

Oligonucleotides

GMP Molecules

Targets Recommended: Gap Junction Protein

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N6684

Deoxynivalenol Maximum Cited Publications 16 Publications Verification Vomitoxin	P-glycoprotein	Metabolic Disease
Deoxynivalenol, an orally active mycotoxin of the trichothecenes family, crosses the intestinal mucosa by a paracellular pathway through the tight junctions. The Deoxynivalenol transport is not affected by P-glycoprotein (PgP) or multidrug resistance-associated proteins (MRPs) inhibitors .

HY-148033

Trimethyl chitosan N,N,N-Trimethylchitosan	Drug Derivative	Others
Trimethyl chitosan (N,N,N-Trimethylchitosan) is a multifunctional polymer and a derivative of Chitosan (HY-B2144A). Trimethyl chitosan targets the absorption enhancing proteins of tight junctions of intestinal and mucosal epithelial cells, induces tight junction protein rearrangement, and increases intercellular permeability. Trimethyl chitosan can stimulate the activity of promoting transmembrane transport of hydrophilic drugs (such as peptides and proteins) and can be used for drug delivery and synthesis of nanoparticles .

HY-113283

Homogentisic acid	Amyloid-β Natriuretic Peptide Receptor (NPR) α-synuclein Transthyretin (TTR) Claudin	Neurological Disease Metabolic Disease Cancer
Homogentisic acid is an orally active, blood-brain barrier-permeable amyloidogenic compound that functions as both an amyloid component and a pigment precursor. Accumulation of homogentisic acid downregulates tight junction proteins (such as claudin-5, occludin, ZO-1) and impairs blood-brain barrier integrity. Homogentisic acid and its oxidation product benzoquinone acetic acid not only induce the aggregation and fibrosis of multiple proteins (such as Aβ_1-42, α-synuclein, SAA, Transthyretin (TTR), atrial natriuretic peptide), but also trigger oxidative stress, damage to the Wnt/β-catenin pathway, and neurotoxicity, leading to ochronosis pigment deposition and synaptic dysfunction. At specific concentrations, homogentisic acid exerts no cytotoxicity or genotoxicity on human peripheral blood lymphocytes, and even counteracts the genotoxicity induced by Irinotecan (HY-16562). Homogentisic acid serves as an important tool molecule for investigating the mechanisms of diseases including ochronosis, secondary amyloidosis, Alzheimer's disease, and colorectal cancer .

HY-N0671

Rhapontin 2 Publications Verification Rhaponiticin	Apoptosis	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
Rhapontin (Rhaponiticin) is an orally aactive SIRT1 agonist and AMPK activator with anti-inflammatory and anti-fibrotic activities. Rhapontin inhibits NLRP3 inflammasome activation by activating SIRT1 and inhibits TGF-β/Smad signaling via the AMPK pathway. Rhapontin reduces intestinal and lung inflammation, inhibits fibroblast differentiation and extracellular matrix deposition, and enhances tight junction protein expression to repair epithelial barriers. Rhapontin can be used in the study of inflammatory bowel diseases (such as ulcerative colitis) and pulmonary fibrosis .

HY-N2376

Chrysin-7-O-glucuronide 1 Publications Verification	Glycosidase Amylases NF-κB	Metabolic Disease Inflammation/Immunology
Chrysin-7-O-glucuronide is a flavonoid found in Scutellaria baicalensis. Chrysin-7-O-glucuronide inhibits α-glucosidase and α-amylase with IC₅₀ values of 612.13 and 980.73 μg/mL. Chrysin-7-O-glucuronide suppresses NF-κB signaling activity. Chrysin-7-O-glucuronide scavenges free radicals, acts as a tight junction protector, and mitigates intestinal mucosal barrier injury. Chrysin-7-O-glucuronide can be used for the research of type 2 diabetes and severe acute pancreatitis-induced intestinal mucosal barrier injury .

HY-N0634

Cimifugin 1 Publications Verification Cimitin	NF-κB	Inflammation/Immunology
Cimifugin (Cimitin) is a bioactive component of Cimicifuga racemosa, a Chinese herb. Cimifugin suppresses allergic inflammation by reducing epithelial derived initiative key factors via regulating tight junctions . Cimifugin reduces the migration and chemotaxis of RAW264.7 cells and inhibits the release of inflammatory factors and activation of MAPKs and NF-κB signaling pathways induced by LPS .

HY-114426A

AT-1002 TFA	Gap Junction Protein	Metabolic Disease
AT-1002 TFA, a 6-mer synthetic peptide , is a tight *junction* regulator and absorption enhancer .

HY-128852

N-Acetyl-D-galactosamine, 98%	Galectin Endogenous Metabolite	Others
N-Acetyl-D-galactosamine (GalNAc) is a terminal essential amino sugar derived from galactose and forms the antigens of blood group A in humans. N-Acetyl-D-galactosamine (GalNAc) interact with Soya bean agglutinin (SBA), hence decreasing the effects of SBA on cellular membrane permeability and tight junction protein expression in piglets . N-Acetyl-D-galactosamine (GalNAc) inhibits the hemagglutinating activity by the lectin .

HY-P991200

OM-7D3-B3	HCV Claudin	Infection
OM-7D3-B3 is an antibody-based antiviral agent targeting the tight junction protein CLDN1 (K_d=4 nM). By binding to the first extracellular domain of CLDN1, OM-7D3-B3 disrupts the formation of the CLDN1-CD81 co-receptor complex, thereby effectively inhibiting the entry of hepatitis C virus (HCV). OM-7D3-B3 not only prevents de novo and chronic HCV infections in humanized liver chimeric mice and uPA-SCID mice transplanted with human livers, but also exhibits favorable safety with no toxic effects observed. OM-7D3-B3 serves as a critical tool for research on HCV infection mechanisms and antiviral drug development .

HY-140741

DSPE-PEG2000-OH 1 Publications Verification	Biochemical Assay Reagents	Inflammation/Immunology
DSPE-PEG2000-OH is an absorption enhancer. DSPE-PEG2000-OH reduces the expression levels of ZO-1 and Occludin. DSPE-PEG2000-OH enhances the pulmonary absorption of poorly absorbable macromolecules via the paracellular pathway without altering pulmonary membrane fluidity .

HY-P99413

IMAB027 ASP1650	HCV	Cancer
IMAB027 (ASP1650) is a specific anti-CLDN6 mAb, while CLDN6 (Claudin 6) is a tight junction membrane protein, aberrantly expressed in various human cancer types, ovarian cancers particularly. IMAB 027 shows anti-tumor activity, and induces apoptosis in CLDN6 ⁺ ovarian and testicular cancer cell lines .

HY-135783

AT 1001 1 Publications Verification	nAChR	Neurological Disease Metabolic Disease Inflammation/Immunology
AT 1001 is an orally effective α3β4 nicotinic acetylcholine receptor (α3β4 nAChR) antagonist with a K_i value of 2.64 nM. AT 1001 reversibly blocks Epibatidine (HY-101078)-induced inward currents in HEK cells transfected with α3β4 nAChR. AT 1001 dose-dependently blocks nicotine self-administration behavior in rats, alleviates gluten-induced gastrointestinal symptoms, blocks tight junction toxin-induced immune responses, and reduces the incidence of type 1 diabetes in rats. AT 1001 can be used in the research of nicotine addiction and celiac disease .

HY-P5523A

iE-DAP dihydrochloride	NOD-like Receptor (NLR) NF-κB Interleukin Related	Metabolic Disease
iE-DAP dihydrochloride is a Nod1 agonist. iE-DAP dihydrochloride activates NOD1, which in turn activates the NF-κB signaling pathway and MLCK signaling pathway, inducing cellular inflammatory responses and tight junction disruption. iE-DAP dihydrochloride downregulates the expression of ZO-1 and Occludin genes. iE-DAP dihydrochloride increases the secretion of IL-6, GRO-α, MCP-1, IL-8 and MIP-1β in term human trophoblast cell cultures. iE-DAP dihydrochloride triggers preterm birth in pregnant mice, reduces fetal body weight, and induces fetal inflammation. iE-DAP dihydrochloride can be used in studies related to mastitis and preterm birth .

HY-W013636C

2-Ketoglutaric acid potassium 5+ Cited Publications Alpha-Ketoglutaric acid potassium	Tyrosinase Endogenous Metabolite TNF Receptor	Neurological Disease Metabolic Disease
2-Ketoglutaric acid (Alpha-Ketoglutaric acid) (potassium) is an intermediate in the production of ATP or GTP in the Krebs cycle. 2-Ketoglutaric acid potassium is a reversible and orally active inhibitor of tyrosinase with an IC₅₀ value of 15 mM. 2-Ketoglutaric acid potassium also acts as the major carbon skeleton for nitrogen-assimilatory reactions. 2-Ketoglutaric acid potassium significantly suppresses abnormal intestinal permeability, delocalization of tight junction proteins from the intestinal cells, expression of TNFα in vitro and in vivo. 2-Ketoglutaric acid potassium directly binds to TAK1, and inhibits the TRAF6-TAK1 interaction. 2-Ketoglutaric acid potassium also alleviates inflammatory bowel disease (IBD) symptoms and gut microbiota dysbiosis, evident by the improvements in the intestine length .

HY-136642

Fluocinolone	Glucocorticoid Receptor	Inflammation/Immunology
Fluocinolone is a potent steroid with highly selective glucocorticoid receptor agonist activity. Fluocinolone stabilizes the blood-retinal barrier by enhancing endothelial tight junctions, inhibiting the VEGF pathway and inflammatory factors. Fluocinolone has high lipophilicity, enabling long-term sustained release in the vitreous. Fluocinolone is used in research related to dermatological diseases, diabetic macular edema, uveitis and oral lichen planus .

HY-N4031

Humantenine	Anaplastic lymphoma kinase (ALK) METTL3	Inflammation/Immunology
Humantenine is a highly toxic indole alkaloid from Gelsemium elegans (Gardn. & Champ.) Benth. that binds to RNA m6A modification regulatory proteins (ALKBH5, METTL). Humantenine stably binds via hydrogen bonding and hydrophobic interactions and disrupts the m6A methylation level of target genes, thereby impairing the expression of intestinal epithelial cell tight junction and cytoskeleton-related genes, causing intestinal barrier dysfunction and significant intestinal cytotoxicity. The intraperitoneal injection LD₅₀ values of Humantenine are <1 mg/kg in mice, 1.2 mg/kg in male rats and 1.5 mg/kg in female rats, respectively. Species differences exist in the metabolism of Humantenine in human, porcine, goat and rat liver microsomes, and demethylation, dehydrogenation and oxidation occur in liver microsomes .

HY-N0671R

Rhapontin (Standard) 2 Publications Verification Rhaponiticin (Standard)	Reference Standards Apoptosis	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
Rhapontin (Standard) is the analytical standard of Rhapontin (HY-N0671). This product is intended for research and analytical applications. Rhapontin (Rhaponiticin) is an orally aactive SIRT1 agonist and AMPK activator with anti-inflammatory and anti-fibrotic activities. Rhapontin inhibits NLRP3 inflammasome activation by activating SIRT1 and inhibits TGF-β/Smad signaling via the AMPK pathway. Rhapontin reduces intestinal and lung inflammation, inhibits fibroblast differentiation and extracellular matrix deposition, and enhances tight junction protein expression to repair epithelial barriers. Rhapontin can be used in the study of inflammatory bowel diseases (such as ulcerative colitis) and pulmonary fibrosis .

HY-114426

AT-1002	Gap Junction Protein	Metabolic Disease
AT-1002, a 6-mer synthetic peptide , is a tight *junction* regulator and absorption enhancer .

HY-N6612B

Glucuronic acid sodium 1 Publications Verification	Bacterial	Inflammation/Immunology
Glucuronic acid sodium is a polysaccharide that exhibits anti-inflammatory activity, supporting the healing of ulcerative colitis. Glucuronic acid sodium also enhances the intestinal barrier by upregulating tight junction proteins like ZO-1 and Occludin. Furthermore, Glucuronic acid sodium plays a role in modulating gut microbiota by increasing beneficial bacterial populations while suppressing harmful ones.

HY-P3828

Biotin-myelin basic protein (94-102)	Fluorescent Dye	Neurological Disease
Biotin-myelin basic protein (94-102) is a peptide fragemt. Myelin basic protein is responsible for adhesion of the cytosolic surfaces of multilayered compact myelin, it plays an important role in the process of myelination of nerves in the nervous system. Myelin basic protein also acts as a membrane actin-binding protein, which might allow it to participate in transmission of extracellular signals to the cytoskeleton in oligodendrocytes and tight junctions in myelin .

HY-I0746

3-Aminobenzoic acid m-Aminobenzoic acid; 3ABA	Endogenous Metabolite	Neurological Disease Inflammation/Immunology
3-Aminobenzoic acid (3-ABA) is an orally active anti-inflammatory agent targeting the tight junction (TJ) regulatory pathways in intestinal epithelial cells. 3-Aminobenzoic acid improves intestinal inflammation by enhancing intestinal barrier integrity and reducing epithelial permeability. It can be used in studies related to improving gut health. Additionally, 3-Aminobenzoic acid analogs can act as γ-aminobutyric acid transaminase (GABA-AT) inhibitors, exhibiting anticonvulsant effects .

HY-P5641

Pleurocidin 1 Publications Verification	Bacterial p38 MAPK NF-κB NADH Dehydrogenase Antibiotic	Infection Inflammation/Immunology
Pleurocidin is an Antimicrobial peptide. Pleurocidin is derived from the skin mucosa or intestinal secretions of Pseudopleuronectes americanus. Pleurocidin inhibits the expression of key proteins in the MAPK and NF-κB inflammatory signaling pathways. Pleurocidin alters serum inflammatory and immune cytokine levels, regulates the down-regulation of tight junction proteins, and modulates the intestinal flora. Pleurocidin exerts antibacterial activity by inducing bacterial membrane damage, hydroxyl radical formation, and NADH depletion, and also produces a synergistic effect with Antibiotics. Pleurocidin alleviates DSS-induced ulcerative colitis. Pleurocidin can be used for research on ulcerative colitis, bacterial infections, and bacterial biofilm-related infections .

HY-P5523

iE-DAP	NOD-like Receptor (NLR) NF-κB Interleukin Related	Metabolic Disease
iE-DAP is a Nod1 agonist. iE-DAP activates NOD1, which in turn activates the NF-κB signaling pathway and MLCK signaling pathway, inducing cellular inflammatory responses and tight junction disruption. iE-DAP downregulates the expression of ZO-1 and Occludin genes. iE-DAP increases the secretion of IL-6, GRO-α, MCP-1, IL-8 and MIP-1β in term human trophoblast cell cultures. iE-DAP triggers preterm birth in pregnant mice, reduces fetal body weight, and induces fetal inflammation. iE-DAP is applicable to research related to mastitis and preterm birth .

HY-N6684R

Deoxynivalenol (Standard) Vomitoxin (Standard)	P-glycoprotein Reference Standards	Metabolic Disease
Deoxynivalenol (Standard) is the analytical standard of Deoxynivalenol. This product is intended for research and analytical applications. Deoxynivalenol, an orally active mycotoxin of the trichothecenes family, crosses the intestinal mucosa by a paracellular pathway through the tight junctions. The Deoxynivalenol transport is not affected by P-glycoprotein (PgP) or multidrug resistance-associated proteins (MRPs) inhibitors .

HY-N11422R

Mycaminosyltylonolide (Standard)	Reference Standards Antibiotic Bacterial	Infection
Deoxynivalenol (Standard) is the analytical standard of Deoxynivalenol. This product is intended for research and analytical applications. Deoxynivalenol, an orally active mycotoxin of the trichothecenes family, crosses the intestinal mucosa by a paracellular pathway through the tight junctions. The Deoxynivalenol transport is not affected by P-glycoprotein (PgP) or multidrug resistance-associated proteins (MRPs) inhibitors .

HY-N13240

Ginseng Extract	Others	Others
Ginseng Extract is a ginseng extract, and its components include: Ginsenosides. Ginseng Extract is an excellent animal nutrition feed additive that can reduce the negative effects of heat stress on animal physiology. Studies have shown that Ginseng Extract can prolong the survival time of Caenorhabditis elegans under heat stress, and its mechanism is related to the upregulation of gene expression of specific heat shock proteins and tight junction proteins. .

HY-N0634R

Cimifugin (Standard) Cimitin (Standard)	Reference Standards NF-κB	Inflammation/Immunology
Cimifugin (Standard) is the analytical standard of Cimifugin. This product is intended for research and analytical applications. Cimifugin (Cimitin) is a bioactive component of Cimicifuga racemosa, a Chinese herb. Cimifugin suppresses allergic inflammation by reducing epithelial derived initiative key factors via regulating tight junctions . Cimifugin reduces the migration and chemotaxis of RAW264.7 cells and inhibits the release of inflammatory factors and activation of MAPKs and NF-κB signaling pathways induced by LPS .

HY-P11149

Human Defensin-5 (1-9)	Bacterial	Infection Metabolic Disease
Human Defensin-5 (1-9) is an orally active antimicrobial peptide. Human Defensin-5 (1-9) can inhibit metabolic disorders induced by Western-style diet (WSD) or Western-style diet with fructose (WSDF). Human Defensin-5 (1-9) enhances intestinal barrier function by upregulating the gene expression of ileal tight junction protein and mucins. Human Defensin-5 (1-9) can be used for the study of obesity and related metabolic diseases .

HY-136642R

Fluocinolone (Standard)	Reference Standards Glucocorticoid Receptor	Inflammation/Immunology
Fluocinolone (Standard) is the analytical standard of Fluocinolone (HY-136642). This product is intended for research and analytical applications. Fluocinolone is a potent steroid with highly selective glucocorticoid receptor agonist activity. Fluocinolone stabilizes the blood-retinal barrier by enhancing endothelial tight junctions, inhibiting the VEGF pathway and inflammatory factors. Fluocinolone has high lipophilicity, enabling long-term sustained release in the vitreous. Fluocinolone is used in research related to dermatological diseases, diabetic macular edema, uveitis and oral lichen planus .

HY-I0746R

3-Aminobenzoic acid (Standard) m-Aminobenzoic acid (Standard); 3ABA (Standard)	Reference Standards Endogenous Metabolite	Neurological Disease Inflammation/Immunology
3-Aminobenzoic acid (Standard) is the analytical standard of 3-Aminobenzoic acid. This product is intended for research and analytical applications. 3-Aminobenzoic acid (3-ABA) is an orally active anti-inflammatory agent targeting the tight junction (TJ) regulatory pathways in intestinal epithelial cells. 3-Aminobenzoic acid improves intestinal inflammation by enhancing intestinal barrier integrity and reducing epithelial permeability. It can be used in studies related to improving gut health. Additionally, 3-Aminobenzoic acid analogs can act as γ-aminobutyric acid transaminase (GABA-AT) inhibitors, exhibiting anticonvulsant effects .

HY-N1516R

Ganoderenic acid D (Standard)	Reference Standards Apoptosis	Cancer
3-Aminobenzoic acid (Standard) is the analytical standard of 3-Aminobenzoic acid. This product is intended for research and analytical applications. 3-Aminobenzoic acid (3-ABA) is an orally active anti-inflammatory agent targeting the tight junction (TJ) regulatory pathways in intestinal epithelial cells. 3-Aminobenzoic acid improves intestinal inflammation by enhancing intestinal barrier integrity and reducing epithelial permeability. It can be used in studies related to improving gut health. Additionally, 3-Aminobenzoic acid analogs can act as γ-aminobutyric acid transaminase (GABA-AT) inhibitors, exhibiting anticonvulsant effects .

HY-171837A

t9,t11,c15-CLNA	TNF Receptor Interleukin Related SOD	Inflammation/Immunology
t9,t11,c15-CLNA is a conjugated linolenic acid (CLNA) isomer produced by Lactobacillus plantarum ZS2058. t9,t11,c15-CLNA has the main activities of anti-inflammatory, antioxidant and improving intestinal barrier function. The regulatory mechanism of t9,t11,c15-CLNA includes upregulation of tight junction proteins, inhibition of pro-inflammatory cytokines (such as TNF-α, IL-6) and activation of antioxidant enzymes (such as SOD, CAT). t9,t11,c15-CLNA can be used in the study of inflammatory bowel diseases (such as colitis) .

HY-N2376R

Chrysin-7-O-glucuronide (Standard)	Reference Standards Glycosidase Amylases NF-κB	Metabolic Disease Inflammation/Immunology
Chrysin-7-O-glucuronide (Standard) is the analytical standard of Chrysin-7-O-glucuronide (Hy-N2376). This product is intended for research and analytical applications. Chrysin-7-O-glucuronide is a flavonoid found in Scutellaria baicalensis. Chrysin-7-O-glucuronide inhibits α-glucosidase and α-amylase with IC₅₀ values of 612.13 and 980.73 μg/mL. Chrysin-7-O-glucuronide suppresses NF-κB signaling activity. Chrysin-7-O-glucuronide scavenges free radicals, acts as a tight junction protector, and mitigates intestinal mucosal barrier injury. Chrysin-7-O-glucuronide can be used for the research of type 2 diabetes and severe acute pancreatitis-induced intestinal mucosal barrier injury .

HY-112005G

DOPE Dioleoylphosphatidylethanolamine; 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine	Ferroptosis Glutathione Peroxidase ACSL Family Amino acid Transporter	Neurological Disease Inflammation/Immunology
DOPE GMP is DOPE (HY-112005) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. DOPE (Dioleoylphosphatidylethanolamine; 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine) is an orally active inhibitor of ferroptosis with anti-inflammatory and intestinal barrier maintenance activities. DOPE regulates the expression of ACSL4, SLC7A11 and GPX4 to restore the redox system balance, thereby reducing the levels of lipid peroxides, iron ions and intestinal inflammatory factors (IL-1β and IL-6). DOPE promotes the migration and proliferation of intestinal epithelial cells and increases the level of tight junction proteins; it also destabilizes endosomal membranes, mediates the conjugation of RVG peptides with mesenchymal stem cell-derived exosomes to enhance brain targeting. DOPE can be applied to research related to neonatal necrotizing enterocolitis and Alzheimer's disease .

HY-P11785

Cpe30 MT2	Claudin	Cancer
Cpe30 MT2 is a short peptide that binds tightly junction protein Claudin‑4 (CLDN4) with high affinity, with a K_d value of 1.97 nM. Cpe30 MT2 can be used for the synthesis of PET molecular imaging probes targeting pancreatic cancer .

HY-182589

SRP-001	FAAH Potassium Channel	Neurological Disease Metabolic Disease
SRP-001 is an orally active, blood-brain barrier-permeable analgesic and antipyretic agent. SRP-001 reduces the expression level of FAAH, mildly inhibits hERG currents, generates AM404 (HY-101388), and maintains the integrity of hepatic tight junctions. SRP-001 exerts analgesic, antipyretic, and antinociceptive effects .

HY-N17783A

Sanleng acid	Endogenous Metabolite	Inflammation/Immunology
Sanleng acid is an unsaturated fatty acid compound that can be isolated from the hexane extract of Magnolia sieboldii (MsHE). MsHE can inhibit the expression of inflammatory mediators (such as COX-2) and pro-inflammatory cytokines (such as TNF-α, IL-1β), and increase the expression of tight junction proteins (claudin-4, claudin-5) to protect epithelial cell barrier function, thus exerting anti-inflammatory activity. Related compounds may be used in research related to reflux esophagitis (RE).

Cat. No.	Product Name

HY-L028

CNS-Penetrant Compound Library	1,096 compounds
The blood-brain barrier (BBB) is the complex network of brain microvessels. It protects the brain from the external bloodstream environment and supplies the brain with the required nutrients for normal function. However, blood-brain barrier is also the obstacle to deliver beneﬁcial drugs to treat CNS (central nervous system) diseases or brain tumors, as it has the least permeable capillaries in the entire body due to physical barriers (tight junctions). Therefore, it is crucial to discover drugs which can cross this barrier for the treatment of brain-based diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and epilepsy. MCE offers a unique collection of 1,096 compounds with confirmed CNS-Penetrant property. It’s a useful tool for the discovery of drugs used for brain diseases, such as brain tumors, mental disorders, and neurodegenerative diseases.

CNS-Penetrant Compound Library

1,096 compounds

The blood-brain barrier (BBB) is the complex network of brain microvessels. It protects the brain from the external bloodstream environment and supplies the brain with the required nutrients for normal function. However, blood-brain barrier is also the obstacle to deliver beneﬁcial drugs to treat CNS (central nervous system) diseases or brain tumors, as it has the least permeable capillaries in the entire body due to physical barriers (tight junctions). Therefore, it is crucial to discover drugs which can cross this barrier for the treatment of brain-based diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and epilepsy.

MCE offers a unique collection of 1,096 compounds with confirmed CNS-Penetrant property. It’s a useful tool for the discovery of drugs used for brain diseases, such as brain tumors, mental disorders, and neurodegenerative diseases.

HY-L919

MCE CNS BBB Lead-like Library	27,503 compounds
With the aging population and increasing competitive pressures, neurodegenerative diseases of the central nervous system (CNS) have become a serious medical challenge in modern society, including Parkinson's disease, Alzheimer's disease, brain tumors, and multiple sclerosis. However, the success rate of CNS drug development remains remarkably low, primarily due to the blood-brain barrier (BBB). The blood-brain barrier (BBB) is a semipermeable barrier structure that surrounds the microvasculature of the CNS. In capillaries, the wedged endothelial cells are tightly packed and wedge-shaped, lining the interior of the vessels to form extensive tight junctions. Along with a range of receptors, transporters, efflux pumps, and other cellular components, this barrier regulates the entry and exit of molecules between the bloodstream and the brain. The intact BBB blocks the passage of most blood-borne substances into the brain, preventing nearly 100% of large-molecule drugs and over 98% of small-molecule drugs from entering. Compared to non-CNS drugs, physicochemical properties such as hydrogen bonds, lipophilicity, and molecular weight significantly influence a compound's ability to cross the BBB. Using artificial intelligence (AI) algorithms to predict BBB permeability, a predicted value greater than 0.75 indicates that the compound has strong potential to cross the BBB, providing a promising starting point for CNS drug discovery.

MCE CNS BBB Lead-like Library

27,503 compounds

With the aging population and increasing competitive pressures, neurodegenerative diseases of the central nervous system (CNS) have become a serious medical challenge in modern society, including Parkinson's disease, Alzheimer's disease, brain tumors, and multiple sclerosis. However, the success rate of CNS drug development remains remarkably low, primarily due to the blood-brain barrier (BBB). The blood-brain barrier (BBB) is a semipermeable barrier structure that surrounds the microvasculature of the CNS. In capillaries, the wedged endothelial cells are tightly packed and wedge-shaped, lining the interior of the vessels to form extensive tight junctions. Along with a range of receptors, transporters, efflux pumps, and other cellular components, this barrier regulates the entry and exit of molecules between the bloodstream and the brain. The intact BBB blocks the passage of most blood-borne substances into the brain, preventing nearly 100% of large-molecule drugs and over 98% of small-molecule drugs from entering. Compared to non-CNS drugs, physicochemical properties such as hydrogen bonds, lipophilicity, and molecular weight significantly influence a compound's ability to cross the BBB. Using artificial intelligence (AI) algorithms to predict BBB permeability, a predicted value greater than 0.75 indicates that the compound has strong potential to cross the BBB, providing a promising starting point for CNS drug discovery.

Cat. No.	Product Name	Type

HY-112005G

DOPE Dioleoylphosphatidylethanolamine; 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine	Fluorescent Dyes
DOPE GMP is DOPE (HY-112005) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. DOPE (Dioleoylphosphatidylethanolamine; 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine) is an orally active inhibitor of ferroptosis with anti-inflammatory and intestinal barrier maintenance activities. DOPE regulates the expression of ACSL4, SLC7A11 and GPX4 to restore the redox system balance, thereby reducing the levels of lipid peroxides, iron ions and intestinal inflammatory factors (IL-1β and IL-6). DOPE promotes the migration and proliferation of intestinal epithelial cells and increases the level of tight junction proteins; it also destabilizes endosomal membranes, mediates the conjugation of RVG peptides with mesenchymal stem cell-derived exosomes to enhance brain targeting. DOPE can be applied to research related to neonatal necrotizing enterocolitis and Alzheimer's disease .

DOPE

Dioleoylphosphatidylethanolamine; 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine

Fluorescent Dyes

DOPE GMP is DOPE (HY-112005) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. DOPE (Dioleoylphosphatidylethanolamine; 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine) is an orally active inhibitor of ferroptosis with anti-inflammatory and intestinal barrier maintenance activities. DOPE regulates the expression of ACSL4, SLC7A11 and GPX4 to restore the redox system balance, thereby reducing the levels of lipid peroxides, iron ions and intestinal inflammatory factors (IL-1β and IL-6). DOPE promotes the migration and proliferation of intestinal epithelial cells and increases the level of tight junction proteins; it also destabilizes endosomal membranes, mediates the conjugation of RVG peptides with mesenchymal stem cell-derived exosomes to enhance brain targeting. DOPE can be applied to research related to neonatal necrotizing enterocolitis and Alzheimer's disease .

Cat. No.	Product Name	Type

HY-148033

Trimethyl chitosan N,N,N-Trimethylchitosan	Biochemical Assay Reagents
Trimethyl chitosan (N,N,N-Trimethylchitosan) is a multifunctional polymer and a derivative of Chitosan (HY-B2144A). Trimethyl chitosan targets the absorption enhancing proteins of tight junctions of intestinal and mucosal epithelial cells, induces tight junction protein rearrangement, and increases intercellular permeability. Trimethyl chitosan can stimulate the activity of promoting transmembrane transport of hydrophilic drugs (such as peptides and proteins) and can be used for drug delivery and synthesis of nanoparticles .

Trimethyl chitosan

N,N,N-Trimethylchitosan

Biochemical Assay Reagents

Trimethyl chitosan (N,N,N-Trimethylchitosan) is a multifunctional polymer and a derivative of Chitosan (HY-B2144A). Trimethyl chitosan targets the absorption enhancing proteins of tight junctions of intestinal and mucosal epithelial cells, induces tight junction protein rearrangement, and increases intercellular permeability. Trimethyl chitosan can stimulate the activity of promoting transmembrane transport of hydrophilic drugs (such as peptides and proteins) and can be used for drug delivery and synthesis of nanoparticles .

HY-128852

N-Acetyl-D-galactosamine, 98%	Biochemical Assay Reagents
N-Acetyl-D-galactosamine (GalNAc) is a terminal essential amino sugar derived from galactose and forms the antigens of blood group A in humans. N-Acetyl-D-galactosamine (GalNAc) interact with Soya bean agglutinin (SBA), hence decreasing the effects of SBA on cellular membrane permeability and tight junction protein expression in piglets . N-Acetyl-D-galactosamine (GalNAc) inhibits the hemagglutinating activity by the lectin .

N-Acetyl-D-galactosamine, 98%

Biochemical Assay Reagents

N-Acetyl-D-galactosamine (GalNAc) is a terminal essential amino sugar derived from galactose and forms the antigens of blood group A in humans. N-Acetyl-D-galactosamine (GalNAc) interact with Soya bean agglutinin (SBA), hence decreasing the effects of SBA on cellular membrane permeability and tight junction protein expression in piglets . N-Acetyl-D-galactosamine (GalNAc) inhibits the hemagglutinating activity by the lectin .

HY-140741

DSPE-PEG2000-OH 1 Publications Verification	Biochemical Assay Reagents
DSPE-PEG2000-OH is an absorption enhancer. DSPE-PEG2000-OH reduces the expression levels of ZO-1 and Occludin. DSPE-PEG2000-OH enhances the pulmonary absorption of poorly absorbable macromolecules via the paracellular pathway without altering pulmonary membrane fluidity .

HY-W013636C

2-Ketoglutaric acid potassium

5+ Cited Publications

Alpha-Ketoglutaric acid potassium

Biochemical Assay Reagents

2-Ketoglutaric acid (Alpha-Ketoglutaric acid) (potassium) is an intermediate in the production of ATP or GTP in the Krebs cycle. 2-Ketoglutaric acid potassium is a reversible and orally active inhibitor of tyrosinase with an IC₅₀ value of 15 mM. 2-Ketoglutaric acid potassium also acts as the major carbon skeleton for nitrogen-assimilatory reactions. 2-Ketoglutaric acid potassium significantly suppresses abnormal intestinal permeability, delocalization of tight junction proteins from the intestinal cells, expression of TNFα in vitro and in vivo. 2-Ketoglutaric acid potassium directly binds to TAK1, and inhibits the TRAF6-TAK1 interaction. 2-Ketoglutaric acid potassium also alleviates inflammatory bowel disease (IBD) symptoms and gut microbiota dysbiosis, evident by the improvements in the intestine length .

HY-112005G

DOPE

Dioleoylphosphatidylethanolamine; 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine

Biochemical Assay Reagents

Cat. No.	Product Name	Target	Research Area

HY-P5523A

iE-DAP dihydrochloride	NOD-like Receptor (NLR) NF-κB Interleukin Related	Metabolic Disease
iE-DAP dihydrochloride is a Nod1 agonist. iE-DAP dihydrochloride activates NOD1, which in turn activates the NF-κB signaling pathway and MLCK signaling pathway, inducing cellular inflammatory responses and tight junction disruption. iE-DAP dihydrochloride downregulates the expression of ZO-1 and Occludin genes. iE-DAP dihydrochloride increases the secretion of IL-6, GRO-α, MCP-1, IL-8 and MIP-1β in term human trophoblast cell cultures. iE-DAP dihydrochloride triggers preterm birth in pregnant mice, reduces fetal body weight, and induces fetal inflammation. iE-DAP dihydrochloride can be used in studies related to mastitis and preterm birth .

HY-P3828

Biotin-myelin basic protein (94-102)	Fluorescent Dye	Neurological Disease
Biotin-myelin basic protein (94-102) is a peptide fragemt. Myelin basic protein is responsible for adhesion of the cytosolic surfaces of multilayered compact myelin, it plays an important role in the process of myelination of nerves in the nervous system. Myelin basic protein also acts as a membrane actin-binding protein, which might allow it to participate in transmission of extracellular signals to the cytoskeleton in oligodendrocytes and tight junctions in myelin .

HY-P5641

Pleurocidin 1 Publications Verification	Bacterial p38 MAPK NF-κB NADH Dehydrogenase Antibiotic	Infection Inflammation/Immunology
Pleurocidin is an Antimicrobial peptide. Pleurocidin is derived from the skin mucosa or intestinal secretions of Pseudopleuronectes americanus. Pleurocidin inhibits the expression of key proteins in the MAPK and NF-κB inflammatory signaling pathways. Pleurocidin alters serum inflammatory and immune cytokine levels, regulates the down-regulation of tight junction proteins, and modulates the intestinal flora. Pleurocidin exerts antibacterial activity by inducing bacterial membrane damage, hydroxyl radical formation, and NADH depletion, and also produces a synergistic effect with Antibiotics. Pleurocidin alleviates DSS-induced ulcerative colitis. Pleurocidin can be used for research on ulcerative colitis, bacterial infections, and bacterial biofilm-related infections .

HY-P5523

iE-DAP	NOD-like Receptor (NLR) NF-κB Interleukin Related	Metabolic Disease
iE-DAP is a Nod1 agonist. iE-DAP activates NOD1, which in turn activates the NF-κB signaling pathway and MLCK signaling pathway, inducing cellular inflammatory responses and tight junction disruption. iE-DAP downregulates the expression of ZO-1 and Occludin genes. iE-DAP increases the secretion of IL-6, GRO-α, MCP-1, IL-8 and MIP-1β in term human trophoblast cell cultures. iE-DAP triggers preterm birth in pregnant mice, reduces fetal body weight, and induces fetal inflammation. iE-DAP is applicable to research related to mastitis and preterm birth .

HY-P11149

Human Defensin-5 (1-9)	Bacterial	Infection Metabolic Disease
Human Defensin-5 (1-9) is an orally active antimicrobial peptide. Human Defensin-5 (1-9) can inhibit metabolic disorders induced by Western-style diet (WSD) or Western-style diet with fructose (WSDF). Human Defensin-5 (1-9) enhances intestinal barrier function by upregulating the gene expression of ileal tight junction protein and mucins. Human Defensin-5 (1-9) can be used for the study of obesity and related metabolic diseases .

HY-P11785

Cpe30 MT2	Claudin	Cancer
Cpe30 MT2 is a short peptide that binds tightly junction protein Claudin‑4 (CLDN4) with high affinity, with a K_d value of 1.97 nM. Cpe30 MT2 can be used for the synthesis of PET molecular imaging probes targeting pancreatic cancer .

Cat. No.	Product Name	Target	Research Area	Image

HY-P991200

OM-7D3-B3	HCV Claudin	Infection
OM-7D3-B3 is an antibody-based antiviral agent targeting the tight junction protein CLDN1 (K_d=4 nM). By binding to the first extracellular domain of CLDN1, OM-7D3-B3 disrupts the formation of the CLDN1-CD81 co-receptor complex, thereby effectively inhibiting the entry of hepatitis C virus (HCV). OM-7D3-B3 not only prevents de novo and chronic HCV infections in humanized liver chimeric mice and uPA-SCID mice transplanted with human livers, but also exhibits favorable safety with no toxic effects observed. OM-7D3-B3 serves as a critical tool for research on HCV infection mechanisms and antiviral drug development .

HY-P99413

IMAB027 ASP1650	HCV	Cancer
IMAB027 (ASP1650) is a specific anti-CLDN6 mAb, while CLDN6 (Claudin 6) is a tight junction membrane protein, aberrantly expressed in various human cancer types, ovarian cancers particularly. IMAB 027 shows anti-tumor activity, and induces apoptosis in CLDN6 ⁺ ovarian and testicular cancer cell lines .

Host:	Rabbit (5)
Reactivity:	Human (5) Mouse (3) Rat (5) Monkey (1)
Application:	IHC-P (3) ICC/IF (3) IHC-F (1) WB (4) FC (1) ELISA (1)
Isotype:	IgG (5)
Conjugation:	Non-conjugated (5)
Clonality:	Polyclonal (2) Monoclonal (2) Recombinant (2)
Modification:	Unmodified (4)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P83694

	ZO-1/TJP1 Antibody (YA3430) 1 Publications Verification ZO1_HUMAN; tight junction protein ZO-1; TJP1; ZO1; tight junction protein 1; Zona occludens protein 1; Zonula occludens protein 1; ZO1 tight junction protein;	WB, IHC-P, ICC/IF	Human, Mouse, Rat, Monkey
	ZO-1/TJP1 Antibody (YA3430) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ZO-1/TJP1.

HY-P82711

	Tight Junction Protein ZO 3 Antibody (YA2456) ZO3; ZO-3	WB	Human, Rat
	Tight Junction Protein ZO 3 Antibody (YA2456) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Tight Junction Protein ZO 3.

HY-P82711A

	Tight Junction Protein ZO 3 Antibody (YA2456)(PBS only) ZO3; ZO-3	WB	Human, Rat
	Tight Junction Protein ZO 3 Antibody (YA2456) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Tight Junction Protein ZO 3.

HY-P81155

	Occludin/OCLN Antibody OCLN_HUMAN; Occludin; Ocl; BLCPMG; PPP1R115; PTORCH1; tight junction protein occludin;	WB, IHC-P, ICC/IF	Human, Mouse, Rat
	Occludin/OCLN Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to Occludin/OCLN.

HY-P81231

	Occludin Antibody 2 Publications Verification Occludin, Occludin-1; Occludin1; Occludin 1; FLJ08163; BLCPMG; FLJ18079; FLJ77961; FLJ94056; MGC34277; Occludin; OCLN; OCLN_HUMAN; tight junction protein occludin.	IHC-P, IHC-F, ICC/IF, FC, ELISA	Human, Mouse, Rat
	Occludin Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to Occludin.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-148033

Trimethyl chitosan N,N,N-Trimethylchitosan		Polymers
Trimethyl chitosan (N,N,N-Trimethylchitosan) is a multifunctional polymer and a derivative of Chitosan (HY-B2144A). Trimethyl chitosan targets the absorption enhancing proteins of tight junctions of intestinal and mucosal epithelial cells, induces tight junction protein rearrangement, and increases intercellular permeability. Trimethyl chitosan can stimulate the activity of promoting transmembrane transport of hydrophilic drugs (such as peptides and proteins) and can be used for drug delivery and synthesis of nanoparticles .

HY-140741

DSPE-PEG2000-OH 1 Publications Verification		Pegylated Lipids
DSPE-PEG2000-OH is an absorption enhancer. DSPE-PEG2000-OH reduces the expression levels of ZO-1 and Occludin. DSPE-PEG2000-OH enhances the pulmonary absorption of poorly absorbable macromolecules via the paracellular pathway without altering pulmonary membrane fluidity .

Targets Recommended: Gap Junction Protein

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-112005G

DOPE Dioleoylphosphatidylethanolamine; 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine	Ferroptosis Glutathione Peroxidase ACSL Family Amino acid Transporter	Neurological Disease Inflammation/Immunology
DOPE GMP is DOPE (HY-112005) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. DOPE (Dioleoylphosphatidylethanolamine; 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine) is an orally active inhibitor of ferroptosis with anti-inflammatory and intestinal barrier maintenance activities. DOPE regulates the expression of ACSL4, SLC7A11 and GPX4 to restore the redox system balance, thereby reducing the levels of lipid peroxides, iron ions and intestinal inflammatory factors (IL-1β and IL-6). DOPE promotes the migration and proliferation of intestinal epithelial cells and increases the level of tight junction proteins; it also destabilizes endosomal membranes, mediates the conjugation of RVG peptides with mesenchymal stem cell-derived exosomes to enhance brain targeting. DOPE can be applied to research related to neonatal necrotizing enterocolitis and Alzheimer's disease .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

tight junction

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Antibodies

Oligonucleotides

GMP Molecules

Natural
Products